Nuveen
CTNM

Nuveen’s Contineum Therapeutics CTNM Stock Holding History

Nuveen’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Buy
+35,707
New +$468K ﹤0.01% 3202
2025
Q2 		– Sell
-13,307
Closed -$92.9K – 3441
2025
Q1 		$92.9K Hold
13,307
– – ﹤0.01% 3221
2024
Q4 		$195K Buy
+13,307
New +$211K ﹤0.01% 3210

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen's CTNM Position: Q2 2026 in Review

Nuveen opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 35,707 shares worth $585K. The stake represents ﹤0.01% of the portfolio and ranks #3202 among its holdings. This is a return to the name: Nuveen previously reported a position in CTNM as recently as Q1 2025.

Nuveen first reported a position in CTNM in Q4 2024 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Nuveen held 35,707 shares of Contineum Therapeutics worth $585K as of Q2 2026.
  • Contineum Therapeutics was a new Nuveen position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3202 holding.
  • Nuveen first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.